Skip to content

The efficacy of anamorelin in patients with cachexia associated with chronic obstructive pulmonary disease

Prospective, open-label, interventional study to explore the efficacy of the ghrelin agonist anamorelin in patients with cachexia associated with chronic obstructive pulmonary disease

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs031230446
Enrollment
28
Registered
2023-11-13
Start date
2024-05-28
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

cachexia associated with chronic obstructive pulmonary disease cachexia

Interventions

Anamorelin 100mg is administered orally once daily on an empty stomach, at least one hour before breakfast, daily for 12 weeks.
C000593861
anamorelin

Sponsors

Ikari Jun
Lead Sponsor
Suzuki Takuji
Collaborator

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Adults 18years of age or older at the time of consent 2) Patients diagnosed with COPD 3) Patients with non-arbitrary wight loss of 2% or more within 3-6 months, or BMI 0.5mg/dL 5) Patients receiving appropriate pharmacological therapy for COPD 6) Patients who have been informed of the study and who have given written consent of their own free will

Exclusion criteria

Exclusion criteria: 1) Patients who have been introduced to new inhalation or nutritional therapy during the period from 4 weeks prior to the start of the study to the start of the study 2) Poorly controlled diabetes mellitus 3) Patients with the following contraindications to anamorelin administration a. Patients with a history of hypersensitivity to anamorelin b. Patients with congestive heart failure c. Patients with myocardial infarction or angina pectoris d. Patients with severe conduction defects (e.g., complete atrioventricular block) e. Patients receiving the following drugs (clarithromycin, indinavir, itraconazole, nelfinavir, saquinavir, telaprevir, voriconazole, ritonavir-containing products, cobicistat-containing products) f. Hepatic dysfunction of moderate severity or greater (Child-Pugh Classification B or C) g. Patients with difficulty in oral intake of food due to gastrointestinal obstruction or other organic abnormalities of the gastrointestinal tract. 4) Patients who are pregnant, possibly pregnant, within 28 days postpartum, or lactating. 5) Other patients whom the investigator determines to be unsuitable for the safe conduct of this study.

Design outcomes

Primary

MeasureTime frame
Proportion of patients who maintained or increased lean body mass from baseline at Day85

Secondary

MeasureTime frame
Change from baseline in the following items at Days 29, 57, 85 and 141(only for Day 85 in 7)) 1) lean body mass 2) body weight 3) Grip strength 4) COPD assessment test 5) Geriatric depression scale 6) Council on Nutrition Appetite Questionnaire into Japanese 7) Forced expiratory volume in one second, Forced vital capacity

Contacts

Public ContactRyutaro Hirama

Chiba University Hospital

cdda6829@chiba-u.jp+81-43-222-7171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026